Comparative Pharmacology
Head-to-head clinical analysis: CLEOCIN PHOSPHATE versus CLINDAMYCIN PHOSPHATE IN DEXTROSE 5 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLEOCIN PHOSPHATE versus CLINDAMYCIN PHOSPHATE IN DEXTROSE 5 IN PLASTIC CONTAINER.
CLEOCIN PHOSPHATE vs CLINDAMYCIN PHOSPHATE IN DEXTROSE 5% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Clindamycin phosphate is a prodrug that is hydrolyzed to clindamycin. Clindamycin binds to the 50S subunit of bacterial ribosomes, inhibiting protein synthesis. It exhibits bacteriostatic activity against susceptible bacteria.
Reversibly binds to the 50S subunit of bacterial ribosomes, inhibiting peptide bond formation and protein synthesis. May also act as a bacterial protein synthesis inhibitor by dissociating ribosomes.
600-2700 mg/day IV/IM in 2-4 divided doses. Typical: 600-900 mg IV q8h or 300-600 mg IM q12h.
Adult: 300-600 mg IV every 6-8 hours, up to 2.7 g/day in 3-4 divided doses for severe infections.
None Documented
None Documented
Terminal elimination half-life is 2-3 hours in adults with normal renal and hepatic function; may be prolonged to 4-5 hours in patients with severe hepatic impairment (Child-Pugh C). In neonates, half-life ranges from 8-12 hours, decreasing to adult values by 1 month of age.
The terminal elimination half-life is approximately 2.4 hours in adults with normal renal function, but increases to 3-5 hours in patients with severe hepatic impairment. Renal impairment has minimal effect. In neonates, half-life may be prolonged (up to 8-12 hours).
Approximately 10% as active drug and metabolites in urine, 3.6% in feces; major route is hepatic metabolism to inactive metabolites (N-demethylclindamycin and clindamycin sulfoxide) excreted in bile and feces. Renal excretion accounts for about 10% of the dose, with the remainder eliminated via biliary/fecal route.
Clindamycin is primarily excreted via bile and feces (approximately 90% as metabolites), with renal elimination accounting for about 10% (parent drug and N-demethylated metabolite). Less than 1% is excreted unchanged in urine.
Category C
Category A/B
Lincosamide Antibiotic
Lincosamide Antibiotic